Global and China Neuroendocrine Tumor Drug Market Insights, Forecast to 2027

Global and China Neuroendocrine Tumor Drug Market Insights, Forecast to 2027

Table of Contents
1 Study Coverage
1.1 Neuroendocrine Tumor Drug Product Introduction
1.2 Market by Type
1.2.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type
1.2.2 mTOR Protein Inhibitors
1.2.3 Tyrosine Kinase 3 Inhibitors
1.2.4 Somatostatin Receptor Antagonists
1.2.5 Growth Hormone Releasing Factor Antagonists
1.2.6 Somatostatin Receptor Agonists
1.2.7 Others
1.3 Market by Application
1.3.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Neuroendocrine Tumor Drug Market Size, Estimates and Forecasts
2.1.1 Global Neuroendocrine Tumor Drug Revenue 2016-2027
2.1.2 Global Neuroendocrine Tumor Drug Sales 2016-2027
2.2 Global Neuroendocrine Tumor Drug, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Neuroendocrine Tumor Drug Historical Market Size by Region (2016-2021)
2.3.1 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Neuroendocrine Tumor Drug Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Neuroendocrine Tumor Drug Sales Forecast by Region (2022-2027)
2.4.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Region (2022-2027)
3 Global Neuroendocrine Tumor Drug Competitor Landscape by Players
3.1 Global Top Neuroendocrine Tumor Drug Manufacturers by Sales
3.1.1 Global Neuroendocrine Tumor Drug Sales by Manufacturer (2016-2021)
3.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Neuroendocrine Tumor Drug Manufacturers by Revenue
3.2.1 Key Neuroendocrine Tumor Drug Manufacturers Covered: Ranking by Revenue
3.2.2 Global Neuroendocrine Tumor Drug Revenue by Manufacturers (2016-2021)
3.2.3 Global Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Drug Revenue in 2020
3.2.6 Global Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Neuroendocrine Tumor Drug Price by Manufacturers
3.4 Global Neuroendocrine Tumor Drug Manufacturing Base Distribution, Product Types
3.4.1 Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuroendocrine Tumor Drug Product Type
3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Neuroendocrine Tumor Drug Market Size by Type (2016-2021)
4.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2016-2021)
4.1.2 Global Neuroendocrine Tumor Drug Revenue by Type (2016-2021)
4.1.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2022-2027)
4.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Type (2022-2027)
4.2.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Neuroendocrine Tumor Drug Market Size by Application (2016-2021)
5.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2016-2021)
5.1.2 Global Neuroendocrine Tumor Drug Revenue by Application (2016-2021)
5.1.3 Neuroendocrine Tumor Drug Price by Application (2016-2021)
5.2 Neuroendocrine Tumor Drug Market Size Forecast by Application (2022-2027)
5.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2022-2027)
5.2.3 Global Neuroendocrine Tumor Drug Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Neuroendocrine Tumor Drug Market Size YoY Growth 2016-2027
6.1.1 China Neuroendocrine Tumor Drug Sales YoY Growth 2016-2027
6.1.2 China Neuroendocrine Tumor Drug Revenue YoY Growth 2016-2027
6.1.3 China Neuroendocrine Tumor Drug Market Share in Global Market 2016-2027
6.2 China Neuroendocrine Tumor Drug Market Size by Players (International and Local Players)
6.2.1 China Top Neuroendocrine Tumor Drug Players by Sales (2016-2021)
6.2.2 China Top Neuroendocrine Tumor Drug Players by Revenue (2016-2021)
6.3 China Neuroendocrine Tumor Drug Historic Market Review by Type (2016-2021)
6.3.1 China Neuroendocrine Tumor Drug Sales Market Share by Type (2016-2021)
6.3.2 China Neuroendocrine Tumor Drug Revenue Market Share by Type (2016-2021)
6.3.3 China Neuroendocrine Tumor Drug Price by Type (2016-2021)
6.4 China Neuroendocrine Tumor Drug Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Neuroendocrine Tumor Drug Sales Forecast by Type (2022-2027)
6.4.2 China Neuroendocrine Tumor Drug Revenue Forecast by Type (2022-2027)
6.4.3 China Neuroendocrine Tumor Drug Price Forecast by Type (2022-2027)
6.5 China Neuroendocrine Tumor Drug Historic Market Review by Application (2016-2021)
6.5.1 China Neuroendocrine Tumor Drug Sales Market Share by Application (2016-2021)
6.5.2 China Neuroendocrine Tumor Drug Revenue Market Share by Application (2016-2021)
6.5.3 China Neuroendocrine Tumor Drug Price by Application (2016-2021)
6.6 China Neuroendocrine Tumor Drug Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Neuroendocrine Tumor Drug Sales Forecast by Application (2022-2027)
6.6.2 China Neuroendocrine Tumor Drug Revenue Forecast by Application (2022-2027)
6.6.3 China Neuroendocrine Tumor Drug Price Forecast by Application (2022-2027)
7 North America
7.1 North America Neuroendocrine Tumor Drug Market Size YoY Growth 2016-2027
7.2 North America Neuroendocrine Tumor Drug Market Facts & Figures by Country
7.2.1 North America Neuroendocrine Tumor Drug Sales by Country (2016-2021)
7.2.2 North America Neuroendocrine Tumor Drug Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Tumor Drug Market Size YoY Growth 2016-2027
8.2 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Region
8.2.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2016-2021)
8.2.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Neuroendocrine Tumor Drug Market Size YoY Growth 2016-2027
9.2 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Country
9.2.1 Europe Neuroendocrine Tumor Drug Sales by Country (2016-2021)
9.2.2 Europe Neuroendocrine Tumor Drug Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Neuroendocrine Tumor Drug Market Size YoY Growth 2016-2027
10.2 Latin America Neuroendocrine Tumor Drug Market Facts & Figures by Country
10.2.1 Latin America Neuroendocrine Tumor Drug Sales by Country (2016-2021)
10.2.2 Latin America Neuroendocrine Tumor Drug Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Country
11.2.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2016-2021)
11.2.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 UAE
12 Company Profiles
12.1 Eisai
12.1.1 Eisai Corporation Information
12.1.2 Eisai Description and Business Overview
12.1.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
12.1.5 Eisai Recent Development
12.2 Exelixis, Inc.
12.2.1 Exelixis, Inc. Corporation Information
12.2.2 Exelixis, Inc. Description and Business Overview
12.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Products Offered
12.2.5 Exelixis, Inc. Recent Development
12.3 Foresee Pharmaceuticals, LLC
12.3.1 Foresee Pharmaceuticals, LLC Corporation Information
12.3.2 Foresee Pharmaceuticals, LLC Description and Business Overview
12.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Products Offered
12.3.5 Foresee Pharmaceuticals, LLC Recent Development
12.4 Hutchison MediPharma Limited
12.4.1 Hutchison MediPharma Limited Corporation Information
12.4.2 Hutchison MediPharma Limited Description and Business Overview
12.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Products Offered
12.4.5 Hutchison MediPharma Limited Recent Development
12.5 Intezyne, Inc
12.5.1 Intezyne, Inc Corporation Information
12.5.2 Intezyne, Inc Description and Business Overview
12.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Products Offered
12.5.5 Intezyne, Inc Recent Development
12.6 INVENT Pharmaceuticals, Inc.
12.6.1 INVENT Pharmaceuticals, Inc. Corporation Information
12.6.2 INVENT Pharmaceuticals, Inc. Description and Business Overview
12.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
12.6.5 INVENT Pharmaceuticals, Inc. Recent Development
12.7 Ipsen S.A.
12.7.1 Ipsen S.A. Corporation Information
12.7.2 Ipsen S.A. Description and Business Overview
12.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Products Offered
12.7.5 Ipsen S.A. Recent Development
12.8 Jiangsu Hengrui Medicine Co., Ltd.
12.8.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
12.8.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
12.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Products Offered
12.8.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
12.9 Karyopharm Therapeutics, Inc.
12.9.1 Karyopharm Therapeutics, Inc. Corporation Information
12.9.2 Karyopharm Therapeutics, Inc. Description and Business Overview
12.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Products Offered
12.9.5 Karyopharm Therapeutics, Inc. Recent Development
12.10 Lexicon Pharmaceuticals, Inc.
12.10.1 Lexicon Pharmaceuticals, Inc. Corporation Information
12.10.2 Lexicon Pharmaceuticals, Inc. Description and Business Overview
12.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
12.10.5 Lexicon Pharmaceuticals, Inc. Recent Development
12.11 Eisai
12.11.1 Eisai Corporation Information
12.11.2 Eisai Description and Business Overview
12.11.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Eisai Neuroendocrine Tumor Drug Products Offered
12.11.5 Eisai Recent Development
12.12 Millennium Pharmaceuticals, Inc.
12.12.1 Millennium Pharmaceuticals, Inc. Corporation Information
12.12.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
12.12.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Millennium Pharmaceuticals, Inc. Products Offered
12.12.5 Millennium Pharmaceuticals, Inc. Recent Development
12.13 MolMed S.p.A.
12.13.1 MolMed S.p.A. Corporation Information
12.13.2 MolMed S.p.A. Description and Business Overview
12.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.13.4 MolMed S.p.A. Products Offered
12.13.5 MolMed S.p.A. Recent Development
12.14 Northwest Biotherapeutics, Inc.
12.14.1 Northwest Biotherapeutics, Inc. Corporation Information
12.14.2 Northwest Biotherapeutics, Inc. Description and Business Overview
12.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Northwest Biotherapeutics, Inc. Products Offered
12.14.5 Northwest Biotherapeutics, Inc. Recent Development
12.15 Novartis AG
12.15.1 Novartis AG Corporation Information
12.15.2 Novartis AG Description and Business Overview
12.15.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Novartis AG Products Offered
12.15.5 Novartis AG Recent Development
12.16 OctreoPharm Sciences GmbH
12.16.1 OctreoPharm Sciences GmbH Corporation Information
12.16.2 OctreoPharm Sciences GmbH Description and Business Overview
12.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.16.4 OctreoPharm Sciences GmbH Products Offered
12.16.5 OctreoPharm Sciences GmbH Recent Development
12.17 OXiGENE, Inc.
12.17.1 OXiGENE, Inc. Corporation Information
12.17.2 OXiGENE, Inc. Description and Business Overview
12.17.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2016-2021)
12.17.4 OXiGENE, Inc. Products Offered
12.17.5 OXiGENE, Inc. Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Neuroendocrine Tumor Drug Industry Trends
13.2 Neuroendocrine Tumor Drug Market Drivers
13.3 Neuroendocrine Tumor Drug Market Challenges
13.4 Neuroendocrine Tumor Drug Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neuroendocrine Tumor Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of mTOR Protein Inhibitors
Table 3. Major Manufacturers of Tyrosine Kinase 3 Inhibitors
Table 4. Major Manufacturers of Somatostatin Receptor Antagonists
Table 5. Major Manufacturers of Growth Hormone Releasing Factor Antagonists
Table 6. Major Manufacturers of Somatostatin Receptor Agonists
Table 7. Major Manufacturers of Others
Table 8. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application (2021-2027) & (K Pcs)
Table 9. Global Neuroendocrine Tumor Drug Market Size by Region (K Pcs) & (US$ Million), 2016 VS 2021 VS 2027
Table 10. Global Neuroendocrine Tumor Drug Sales by Regions (2016-2021) & (K Pcs)
Table 11. Global Neuroendocrine Tumor Drug Sales Market Share by Regions (2016-2021)
Table 12. Global Neuroendocrine Tumor Drug Revenue by Regions (2016-2021) & (US$ Million)
Table 13. Global Neuroendocrine Tumor Drug Sales Forecast by Region (2022-2027) & (K Pcs)
Table 14. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Region (2022-2027)
Table 15. Global Neuroendocrine Tumor Drug Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 16. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Region (2022-2027)
Table 17. Global Neuroendocrine Tumor Drug Sales by Manufacturers (2016-2021) (K Pcs)
Table 18. Global Neuroendocrine Tumor Drug Sales Share by Manufacturers (2016-2021)
Table 19. Ranking of Global Top Neuroendocrine Tumor Drug Manufacturers by Revenue (US$ Million) in 2020
Table 20. Neuroendocrine Tumor Drug Revenue by Manufacturers (2016-2021) (US$ Million)
Table 21. Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2016-2021)
Table 22. Global Neuroendocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 23. Global Neuroendocrine Tumor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumor Drug as of 2020)
Table 24. Key Manufacturers Neuroendocrine Tumor Drug Price (2016-2021) (USD/Pcs)
Table 25. Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Neuroendocrine Tumor Drug Product Type
Table 27. Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global Neuroendocrine Tumor Drug Sales by Type (2016-2021) (K Pcs)
Table 30. Global Neuroendocrine Tumor Drug Sales Share by Type (2016-2021)
Table 31. Global Neuroendocrine Tumor Drug Revenue by Type (2016-2021) (US$ Million)
Table 32. Global Neuroendocrine Tumor Drug Revenue Share by Type (2016-2021)
Table 33. Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type (2016-2021) & (USD/Pcs)
Table 34. Global Neuroendocrine Tumor Drug Sales Forecast by Type (2022-2027) & (K Pcs)
Table 35. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Type (2022-2027)
Table 36. Global Neuroendocrine Tumor Drug Revenue Forecast V (2022-2027) & (US$ Million)
Table 37. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Type (2022-2027)
Table 38. Global Neuroendocrine Tumor Drug Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Pcs)
Table 39. Global Neuroendocrine Tumor Drug Sales by Application (2016-2021) (K Pcs)
Table 40. Global Neuroendocrine Tumor Drug Sales Share by Application (2016-2021)
Table 41. Global Neuroendocrine Tumor Drug Revenue by Application (2016-2021) (US$ Million)
Table 42. Global Neuroendocrine Tumor Drug Revenue Share by Application (2016-2021)
Table 43. Neuroendocrine Tumor Drug Average Selling Price (ASP) by Application (2016-2021) & (USD/Pcs)
Table 44. Global Neuroendocrine Tumor Drug Sales Forecast by Application (2022-2027) & (K Pcs)
Table 45. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Application (2022-2027)
Table 46. Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 47. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Application (2022-2027)
Table 48. Global Neuroendocrine Tumor Drug Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Pcs)
Table 49. China Neuroendocrine Tumor Drug Sales (K Pcs) of Key Companies (2016-2021)
Table 50. China Neuroendocrine Tumor Drug Sales Share by Company (2016-2021)
Table 51. China Neuroendocrine Tumor Drug Revenue (US$ Million) by Company (2016-2021)
Table 52. China Neuroendocrine Tumor Drug Revenue Share by Company (2016-2021)
Table 53. China Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2016-2021)
Table 54. China Neuroendocrine Tumor Drug Sales Share by Type (2016-2021)
Table 55. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Type (2016-2021)
Table 56. China Neuroendocrine Tumor Drug Price (USD/Pcs) by Type (2016-2021)
Table 57. China Neuroendocrine Tumor Drug Sales (K Pcs) by Type (2022-2027)
Table 58. China Neuroendocrine Tumor Drug Sales Share by Type (2022-2027)
Table 59. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Type (2022-2027)
Table 60. China Neuroendocrine Tumor Drug Revenue Share by Type (2022-2027)
Table 61. China Neuroendocrine Tumor Drug Price (USD/Pcs) by Type (2022-2027)
Table 62. China Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2016-2021)
Table 63. China Neuroendocrine Tumor Drug Sales Share by Application (2016-2021)
Table 64. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Application (2016-2021)
Table 65. China Neuroendocrine Tumor Drug Price (USD/Pcs) by Application (2016-2021)
Table 66. China Neuroendocrine Tumor Drug Sales (K Pcs) by Application (2022-2027)
Table 67. China Neuroendocrine Tumor Drug Sales Share by Application (2022-2027)
Table 68. China Neuroendocrine Tumor Drug Revenue (US$ Million) Market Share by Application (2022-2027)
Table 69. China Neuroendocrine Tumor Drug Revenue Share by Application (2022-2027)
Table 70. China Neuroendocrine Tumor Drug Price (USD/Pcs) by Application (2022-2027)
Table 71. North America Neuroendocrine Tumor Drug Sales by Country (2016-2021) & (K Pcs)
Table 72. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2016-2021)
Table 73. North America Neuroendocrine Tumor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 74. North America Neuroendocrine Tumor Drug Revenue Market Share by Country (2016-2021)
Table 75. Asia Pacific Neuroendocrine Tumor Drug Sales by Region (2016-2021) & (K Pcs)
Table 76. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Region (2016-2021)
Table 77. Asia Pacific Neuroendocrine Tumor Drug Revenue by Region (2016-2021) & (US$ Million)
Table 78. Asia Pacific Neuroendocrine Tumor Drug Revenue Market Share by Region (2016-2021)
Table 79. Europe Neuroendocrine Tumor Drug Sales by Country (2016-2021) & (K Pcs)
Table 80. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2016-2021)
Table 81. Europe Neuroendocrine Tumor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 82. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2016-2021)
Table 83. Latin America Neuroendocrine Tumor Drug Sales by Country (2016-2021) & (K Pcs)
Table 84. Latin America Neuroendocrine Tumor Drug Sales Market Share by Country (2016-2021)
Table 85. Latin Americaa Neuroendocrine Tumor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 86. Latin America Neuroendocrine Tumor Drug Revenue Market Share by Country (2016-2021)
Table 87. Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2016-2021) & (K Pcs)
Table 88. Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2016-2021)
Table 89. Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2016-2021) & (US$ Million)
Table 90. Middle East and Africa Neuroendocrine Tumor Drug Revenue Market Share by Country (2016-2021)
Table 91. Eisai Corporation Information
Table 92. Eisai Description and Business Overview
Table 93. Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 94. Eisai Neuroendocrine Tumor Drug Product
Table 95. Eisai Recent Development
Table 96. Exelixis, Inc. Corporation Information
Table 97. Exelixis, Inc. Description and Business Overview
Table 98. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 99. Exelixis, Inc. Product
Table 100. Exelixis, Inc. Recent Development
Table 101. Foresee Pharmaceuticals, LLC Corporation Information
Table 102. Foresee Pharmaceuticals, LLC Description and Business Overview
Table 103. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 104. Foresee Pharmaceuticals, LLC Product
Table 105. Foresee Pharmaceuticals, LLC Recent Development
Table 106. Hutchison MediPharma Limited Corporation Information
Table 107. Hutchison MediPharma Limited Description and Business Overview
Table 108. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 109. Hutchison MediPharma Limited Product
Table 110. Hutchison MediPharma Limited Recent Development
Table 111. Intezyne, Inc Corporation Information
Table 112. Intezyne, Inc Description and Business Overview
Table 113. Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 114. Intezyne, Inc Product
Table 115. Intezyne, Inc Recent Development
Table 116. INVENT Pharmaceuticals, Inc. Corporation Information
Table 117. INVENT Pharmaceuticals, Inc. Description and Business Overview
Table 118. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 119. INVENT Pharmaceuticals, Inc. Product
Table 120. INVENT Pharmaceuticals, Inc. Recent Development
Table 121. Ipsen S.A. Corporation Information
Table 122. Ipsen S.A. Description and Business Overview
Table 123. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 124. Ipsen S.A. Product
Table 125. Ipsen S.A. Recent Development
Table 126. Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
Table 127. Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
Table 128. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 129. Jiangsu Hengrui Medicine Co., Ltd. Product
Table 130. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 131. Karyopharm Therapeutics, Inc. Corporation Information
Table 132. Karyopharm Therapeutics, Inc. Description and Business Overview
Table 133. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 134. Karyopharm Therapeutics, Inc. Product
Table 135. Karyopharm Therapeutics, Inc. Recent Development
Table 136. Lexicon Pharmaceuticals, Inc. Corporation Information
Table 137. Lexicon Pharmaceuticals, Inc. Description and Business Overview
Table 138. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 139. Lexicon Pharmaceuticals, Inc. Product
Table 140. Lexicon Pharmaceuticals, Inc. Recent Development
Table 141. Midatech Pharma Plc . Corporation Information
Table 142. Midatech Pharma Plc . Description and Business Overview
Table 143. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 144. Midatech Pharma Plc . Product
Table 145. Midatech Pharma Plc . Recent Development
Table 146. Millennium Pharmaceuticals, Inc. Corporation Information
Table 147. Millennium Pharmaceuticals, Inc. Description and Business Overview
Table 148. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 149. Millennium Pharmaceuticals, Inc. Product
Table 150. Millennium Pharmaceuticals, Inc. Recent Development
Table 151. MolMed S.p.A. Corporation Information
Table 152. MolMed S.p.A. Description and Business Overview
Table 153. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 154. MolMed S.p.A. Product
Table 155. MolMed S.p.A. Recent Development
Table 156. Northwest Biotherapeutics, Inc. Corporation Information
Table 157. Northwest Biotherapeutics, Inc. Description and Business Overview
Table 158. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 159. Northwest Biotherapeutics, Inc. Product
Table 160. Northwest Biotherapeutics, Inc. Recent Development
Table 161. Novartis AG Corporation Information
Table 162. Novartis AG Description and Business Overview
Table 163. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 164. Novartis AG Product
Table 165. Novartis AG Recent Development
Table 166. OctreoPharm Sciences GmbH Corporation Information
Table 167. OctreoPharm Sciences GmbH Description and Business Overview
Table 168. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 169. OctreoPharm Sciences GmbH Product
Table 170. OctreoPharm Sciences GmbH Recent Development
Table 171. OXiGENE, Inc. Corporation Information
Table 172. OXiGENE, Inc. Description and Business Overview
Table 173. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 174. OXiGENE, Inc. Product
Table 175. OXiGENE, Inc. Recent Development
Table 176. Neuroendocrine Tumor Drug Market Trends
Table 177. Neuroendocrine Tumor Drug Market Drivers
Table 178. Neuroendocrine Tumor Drug Market Challenges
Table 179. Neuroendocrine Tumor Drug Market Restraints
Table 180. Neuroendocrine Tumor Drug Customers List
Table 181. Neuroendocrine Tumor Drug Distributors List
Table 182. Research Programs/Design for This Report
Table 183. Key Data Information from Secondary Sources
Table 184. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroendocrine Tumor Drug Product Picture
Figure 2. Global Neuroendocrine Tumor Drug Sales Market Share by Type in 2020 & 2027
Figure 3. mTOR Protein Inhibitors Product Picture
Figure 4. Tyrosine Kinase 3 Inhibitors Product Picture
Figure 5. Somatostatin Receptor Antagonists Product Picture
Figure 6. Growth Hormone Releasing Factor Antagonists Product Picture
Figure 7. Somatostatin Receptor Agonists Product Picture
Figure 8. Others Product Picture
Figure 9. Global Neuroendocrine Tumor Drug Sales Market Share by Application in 2020 & 2027
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Neuroendocrine Tumor Drug Report Years Considered
Figure 14. Global Neuroendocrine Tumor Drug Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Neuroendocrine Tumo

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global 5-Fluorouracil Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76

The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......

Global Carboplatin Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......

Global Neutropenia Drugs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96

The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......

Global Small Molecule Cancer Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......

Global Capecitabine Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80

Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......

Global Oxaliplatin Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104

Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......

Global Cancer Treatment Drugs Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158

According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......

Global Capecitabine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93

According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......

Global Methotrexate Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95

According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs